Sera Prognostics (NASDAQ:SERA) CEO Zhenya Lindgardt Sells 21,158 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 21,158 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $3.15, for a total value of $66,647.70. Following the transaction, the chief executive officer directly owned 811,136 shares in the company, valued at $2,555,078.40. The trade was a 2.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Sera Prognostics Price Performance

Shares of SERA stock opened at $3.10 on Wednesday. The stock’s 50-day moving average is $2.77 and its 200 day moving average is $2.88. Sera Prognostics, Inc. has a 1-year low of $1.37 and a 1-year high of $9.13. The company has a market cap of $116.78 million, a P/E ratio of -3.65 and a beta of 1.00.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. Sera Prognostics had a negative return on equity of 45.86% and a negative net margin of 30,306.48%.The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.05 million. On average, analysts anticipate that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered Sera Prognostics from a “hold” rating to a “sell” rating in a report on Saturday, August 9th.

Institutional Trading of Sera Prognostics

Several large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new position in Sera Prognostics during the 4th quarter worth about $28,000. Sanders Morris Harris LLC increased its holdings in Sera Prognostics by 4.0% during the 1st quarter. Sanders Morris Harris LLC now owns 94,200 shares of the company’s stock worth $347,000 after purchasing an additional 3,600 shares during the period. Rhumbline Advisers increased its holdings in shares of Sera Prognostics by 10.7% in the 1st quarter. Rhumbline Advisers now owns 39,970 shares of the company’s stock valued at $147,000 after acquiring an additional 3,869 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Sera Prognostics by 3.6% in the 1st quarter. Bank of New York Mellon Corp now owns 135,582 shares of the company’s stock valued at $499,000 after acquiring an additional 4,670 shares during the last quarter. Finally, Wells Fargo & Company MN grew its stake in Sera Prognostics by 55.2% during the 4th quarter. Wells Fargo & Company MN now owns 13,192 shares of the company’s stock worth $107,000 after buying an additional 4,691 shares during the last quarter. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.